Host: Chrysalyne D. Schmults, MD, MSCE (Chair)

Guest: Omid Hamid, MD

Guest: Anokhi Jambusaria, MD, MSCE, FAAD

Please note: This activity is no longer available for continuing education credit.

The recent approval of the first immunotherapeutic agent for cutaneous squamous cell carcinoma (cSCC) is changing the way healthcare providers treat patients with inoperable cSCC. In this roundtable discussion, a cSCC survivor draws upon his experience with the cancer when surgery and chemotherapy failed him, as our multidisciplinary faculty panel focus on how to optimally select patients with cSCC for treatment with immunotherapy.